Vera Therapeutics Wins FDA Accelerated Approval For TRUTAKNA In Primary IgA Nephropathy

Vera Therapeutics said the FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression. This regulatory milestone materially improves commercialization prospects for the company. The news is likely to be supportive for VERA shares given the FDA approval for a targeted indication.

Analysis

Vera Therapeutics said the FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression. This regulatory milestone materially improves commercialization prospects for the company. The news is likely to be supportive for VERA shares given the FDA approval for a targeted indication.